Celecoxib treatment alters the gene expression profile of normal colonic mucosa

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 7, 2006, Pages 1382-1391

  Glebov, Oleg K ^a   Rodriguez, Luz M ^a   Lynch, Patrick ^c   Patterson, Sherri ^c   Lynch, Henry ^d   Nakahara, Kenneth ^a   Jenkins, Jean ^a   Cliatt, Janet ^a   Humbyrd, Casey Jo ^a   DeNobile, John ^b   Soballe, Peter ^b   Gallinger, Steven ^e   Buchbinder, Aby ^f   Gordon, Gary ^g   Hawk, Ernest ^a   Kirsch, Ilan R ^a,h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CREIGHTON UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f PFIZER INC   (United States)

^g LUNDBECK RESEARCH USA   (United States)

^h AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; COMPLEMENTARY DNA; PLACEBO; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ADHESION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HETEROZYGOTE; HUMAN; HUMAN CELL; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRESS; T LYMPHOCYTE ACTIVATION;

BIOLOGICAL MARKERS; COLON; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTESTINAL MUCOSA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLACEBOS; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES;

EID: 33746411410     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0866     Document Type: Article

References (84)

1. Darvnenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
2. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
3. Ricchi P, Pignata S, Iaffaioli RV, Daniele B. Cyclo-oxygenase inhibition in colorectal adenomas and cancer. J Clin Gastroenterol 2003;37:281-7.
4. Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003;523-524:137-44.
5. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
6. Zimmermann KC, Sarbia M, Schror K, Weber A-A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998;54:536-40.
7. Peskar BM, Maricic N, Gretzera B, Schuligoi R, Schmassmann A. Role of cyclooxygenase-2 in gastric mucosal defense. Life Sci 2001;69:2993-3003.
8. Bennett A, Del Tacca M. Proceedings: prostaglandins in human colonic carcinoma. Gut 1975;16:409.
9. Bennett A, Tacca MD, Stamford IF, Zebro T. Prostaglandins from tumours of human large bowel. Br J Cancer 1977;35:881-4.
10. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518-23.
11. Sano H, Kawahito Y, Wilder R, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
12. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1995;1258:215-23.
13. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
14. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
15. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6.
16. Fujino H, Regan JW. Prostaglandin F(2α) stimulation of cyclooxygenase-2 promoter activity by the Fp(B) prostanoid receptor. Eur J Pharmacol 2003;465:39-41.
17. Majima M, Amano H, Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003;24:524-9.
18. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype Ep4 in colon carcinogenesis. Cancer Res 2002;62:28-32.
19. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype Ep1 in colon carcinogenesis. Cancer Res 1999;59:5093-6.
20. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor Ep2 in Apc(Delta 716) knockout mice. Nat Med 2001;7:1048-51.
21. Seno H, Oshima M, Ishikawa TO, et al. Cyclooxygenase 2- and prostaglandin E(2) receptor Ep(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 2002;62:506-11.
22. Kubba AK. Non steroidal anti-inflammatory drugs and colorectal cancer: is there a way forward? Eur J Cancer 1999;35:892-901.
23. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511-23.
24. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
25. Marnett LJ, DuBois RN. Cox-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002;42:55-80.
26. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003;88:803-7.
27. Labayle D, Boyer J, Drouhin F, Zarka Y, Fischer D. Sulindac in familial adenomatous polyposis. Lancet 1994;343:417-8.
28. Giardiello FM. Sulindac and polyp regression. Cancer Metastasis Rev 1994;13:279-83.
29. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
30. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
31. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
32. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
33. Kim H, Piao Z, Kim JW, et al. Expression of Hmsh2 and Hmlh1 in colorectal carcinomas with microsatellite instability. Pathol Res Pract 1998;194:3-9.
34. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995;9:48-55.
35. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant rumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645-8.
36. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
37. Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996;111:307-17.
38. Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 2000;18:19-31S.
39. Annie Yu HJ, Lin KM, Ota DM, Lynch HT. Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treat Rev 2003;29:461-70.
40. Glebov OK, Rodriguez LM, Nakahara K, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003;12:755-62.
41. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
42. Gomes LI, Silva RL, Stolf BS, et al. Comparative analysis of amplified and nonamplified RNA for hybridization in cDNA microarray. Anal Biochem 2003;321:244-51.
43. Nygaard V, Loland A, Holden M, et al. Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics 2003;4:11.
44. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-9.
45. Simon R, Lam A. Brb-Arraytools user guide, version 3.2., Biometric Research Branch, National Cancer Institute http://linusncinihgov/brb; 2004.
46. Korn EL, McShane LM, Troendle JF, Rosenwald A, Simon R. Identifying prepost chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002;86:1093-6.
47. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003;19:368-75.
48. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-11.
49. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
50. Harris MA, Clark J, Ireland A, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004;32 Database issue:D258-61.
51. Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
52. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
53. Zeeberg BR, Feng W, Wang G, et al. Gominer: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003;4:R28.
54. Bussey KJ, Kane D, Sunshine M, et al. Matchminer: a tool for batch navigation among gene and gene product identifiers. Genome Biol 2003;4:R27.
55. Zeeberg BR, Riss J, Kane DW, et al. Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics 2004;5:80.
56. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002;32:1372-4, 1376, 1378-9.
57. Singhal S, Kyvernitis CG, Johnson SW, Kaiser LR, Liebman MN, Albelda SM. Microarray data simulator for improved selection of differentially expressed genes. Cancer Biol Ther 2003;2:383-91.
58. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
59. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72.
60. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
61. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003;9:73-8.
62. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
63. 2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004;101:415-6.
64. Dormond O, Ruegg C. Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and protein kinase A. Thromb Haemost 2003;90:577-85.
65. Ruegg C, Dormond O, Mariotti A. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta 2004;1654:51-67.
66. Efstathiou JA, Pignatelli M. Modulation of epithelial cell adhesion in gastrointestinal homeostasis. Am J Pathol 1998;153:341-7.
67. Buda A, Pignatelli M. Cytoskeletal network in colon cancer: from genes to clinical application. Int J Biochem Cell Biol 2004;36:759-65.
68. Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2004;1692:77-102.
69. Weyant MJ, Carothers AM, Bertagnolli ME, Bertagnolli MM. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin Cancer Res 2000;6:949-56.
70. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003;113:881-9.
71. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
72. Zhang Z, DuBois RN. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 2001;20:4450-6.
73. Bottone FG, Jr., Martinez JM, Alston-Mills B, Eling TE. Gene modulation by COX-1 and COX-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 2004;25:349-57.
74. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004;316:421-8.
75. Mori H, Yamada Y, Hirose Y, et al. Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of β-catenin-accumulated crypts as a new biomarker. Eur J Cancer Prev 2002;11 Suppl 2:571-5.
76. Pereira MA. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDS. Adv Exp Med Biol 1999;470:55-63.
77. Charalambous D, Farmer C, O'Brien PE. Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethyl hydrazine treated rats. J Gastroenterol Hepatol 1996;11:88-92.
78. Kishimoto Y, Takata N, Jinnai T, et al. Sulindac and a cyclooxygenase-2 inhibitor, Etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 2000;47:812-9.
79. Roy HK, Karolski WJ, Ratashak A. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer 2001;92:609-15.
80. Buecher B, Thouminot C, Menanteau J, et al. Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats. Reprod Nutr Dev 2003;43:347-56.
81. Brown WA, Skinner SA, Malcontenti-Wilson C, et al. Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 2000;15:1386-92.
82. Yamada Y, Yoshimi N, Hirose Y, et al. Suppression of occurrence and advancement of β-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Jpn J Cancer Res 2001;92:617-23.
83. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165-70.
84. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.